The Proposed EU IP Exception for Generics & Biosimilars Exports - A Cure Worse Than the Disease? (at UC Irvine)

Activity: Talk or presentation typesLecture and oral contribution

Timo Minssen - Invited speaker

The European Union plans to introduce an SPC waiver for Generics and Biosimilars intended for export to countries without patent protection. The laudable aim is to minimize counterfeit medicines in developing countries and to promote more competition and earlier access to generics and biosimilars in Europe. But many challenges remain, including potential conflict with international treaty obligations, enforcement difficulties, and business decisions that could undermine a fundamental assumption of the new policy. This presentation will describe the proposal and discuss how it relates to US positions.
8 Feb 2019

Event (Conference)

TitleBiosimilar Innovation
LocationUniversity of California Irvine- School of Law
Country/TerritoryUnited States
Degree of recognitionInternational event

Number of downloads are based on statistics from Google Scholar and

No data available

ID: 212393072